Last $8.58 USD
Change Today -0.01 / -0.12%
Volume 60.0K
GNCA On Other Exchanges
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

genocea biosciences inc (GNCA) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/10/14 - $23.99
52 Week Low
01/22/15 - $6.15
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

genocea biosciences inc (GNCA) Related Businessweek News

No Related Businessweek News Found

genocea biosciences inc (GNCA) Details

Genocea Biosciences, Inc., a clinical stage biotechnology company, discovers and develops novel vaccines to treat infectious diseases. It uses its proprietary discovery platform, AnTigen Lead Acquisition System, to design vaccines that act through T cell immune responses. The company is developing its lead product candidate, GEN-003, a therapeutic vaccine or an immunotherapy that is in Phase I/IIa trial to treat people with herpes simplex virus-2 (HSV-2) infections. It is also developing GEN-004, a vaccine candidate, which is in Phase I trial to prevent infections caused by pneumococcus; GEN-001 that is in pre-clinical stage for treating chlamydia prophylaxis; GEN-002, which is in pre-clinical stage for the treatment of HSV-2 prophylaxis; and GEN-005 that is in research stage for treating malaria prophylaxis. The company was founded in 2006 and is based in Cambridge, Massachusetts.

44 Employees
Last Reported Date: 03/21/14
Founded in 2006

genocea biosciences inc (GNCA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $334.3K
Chief Medical Officer
Total Annual Compensation: $331.5K
Senior Vice President of Research
Total Annual Compensation: $238.3K
Compensation as of Fiscal Year 2013.

genocea biosciences inc (GNCA) Key Developments

Genocea Biosciences, Inc. Completes Enrollment Early in Phase 2 Dose Optimization Trial of Gen-003 for Treatment of Genital Herpes

Genocea Biosciences, Inc. reported that it has completed enrollment in its Phase 2 dose optimization clinical trial for GEN-003 for the treatment of genital herpes. The company expects to report top-line data from the immediate post-vaccination observation period in late second quarter of 2015. The objective of this trial is to build upon the impressive results observed in the prior Phase 1/2a trial. The Phase 2 dose optimization study enrolled over 300 subjects from 17 institutions in the United States. Subjects were randomized to one of six dosing groups of either 30 micrograms or 60 micrograms per antigen paired with one of three adjuvant doses (25 micrograms, 50 micrograms, or 75 micrograms). A seventh group received placebo. Subjects will receive three doses of GEN-003 or placebo at 21-day intervals. The primary endpoint for the study is the change from baseline in viral shedding rate, a measure of anti-viral activity. The study is also designed to evaluate the impact on genital lesion rates as well as immunogenicity and safety. In the previous Phase 1/2a clinical trial, subjects in the 30 microgram per antigen and 50 microgram of adjuvant dose group experienced, at the immediate post-vaccination observation period, a 52% reduction in viral shedding rate compared to baseline (About Genocea Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies). T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy.

Simeon J. George Retires from the Board of Directors of Genocea Biosciences, Inc

On December 11, 2014, Dr. Simeon J. George notified Genocea Biosciences, Inc. of his decision to retire from the board of directors of the company, effective December 12, 2014. Dr. George has served on the Board since 2009 and has also served as a member of the audit committee and compensation committee.

Eric S. Hoffman Joins Genocea Biosciences, Inc. as Chief Business Officer

Genocea Biosciences, Inc. announced that Eric S. Hoffman has joined the company as chief business officer. Prior to joining Genocea, Eric was vice president of corporate and business development, program management and commercial operations at Idenix Pharmaceuticals, Inc. before its acquisition by Merck in August 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNCA:US $8.58 USD -0.01

GNCA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $9.85 USD -0.29
Argos Therapeutics Inc $8.32 USD +0.34
Eurocine Vaccines AB kr12.50 SEK +0.15
GenVec Inc $3.39 USD +0.10
Vical Inc $1.04 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation GNCA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7,501.2x
Price/Book 3.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4,472.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENOCEA BIOSCIENCES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at